- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004895
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.
PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer.
- Characterize the dose and tolerability of octreotide in this patient population.
OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.
Patients who respond well to study may continue octreotide for palliative effects.
PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611-3013
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Inoperable bowel obstruction secondary to cancer OR
- Metastatic or primary abdominal cancer
- Patient presents with vomiting
- Percutaneous gastrostomy tube allowed
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- ECOG 0-4
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No documented hypersensitivity to octreotide
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Prior chemotherapy allowed
Endocrine therapy:
- Concurrent steroids allowed
Radiotherapy:
- Prior radiotherapy allowed
Surgery:
- Not specified
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: J. Cameron Muir, MD, Robert H. Lurie Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- stage IV rectal cancer
- stage IV colon cancer
- recurrent colon cancer
- recurrent rectal cancer
- recurrent pancreatic cancer
- stage III ovarian epithelial cancer
- stage IV ovarian epithelial cancer
- recurrent ovarian epithelial cancer
- stage III colon cancer
- stage IV pancreatic cancer
- stage IV gastric cancer
- recurrent gastric cancer
- small intestine adenocarcinoma
- unresectable extrahepatic bile duct cancer
- recurrent extrahepatic bile duct cancer
- recurrent small intestine cancer
- small intestine lymphoma
- stage III gastric cancer
- small intestine leiomyosarcoma
- gastrointestinal stromal tumor
- stage I ovarian epithelial cancer
- stage II ovarian epithelial cancer
- stage II rectal cancer
- stage III rectal cancer
- stage II colon cancer
- stage III pancreatic cancer
- peritoneal cavity cancer
- stage I rectal cancer
- stage I gastric cancer
- stage II gastric cancer
- stage I pancreatic cancer
- stage II pancreatic cancer
- nausea and vomiting
- stage I colon cancer
- constipation, impaction, and bowel obstruction
- localized extrahepatic bile duct cancer
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Signs and Symptoms, Digestive
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Intestinal Diseases
- Biliary Tract Diseases
- Pancreatic Diseases
- Neoplasms, Connective Tissue
- Bile Duct Diseases
- Biliary Tract Neoplasms
- Stomach Neoplasms
- Nausea
- Vomiting
- Pancreatic Neoplasms
- Gastrointestinal Stromal Tumors
- Constipation
- Cholangiocarcinoma
- Intestinal Neoplasms
- Intestinal Obstruction
- Bile Duct Neoplasms
- Antineoplastic Agents
- Gastrointestinal Agents
- Antineoplastic Agents, Hormonal
- Octreotide
Other Study ID Numbers
- NU 97X1
- NU-97X1
- NCI-G00-1685
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on octreotide acetate
-
Azidus BrasilSuspended
-
NovartisCompletedDiabetic RetinopathyUnited States
-
Endo PharmaceuticalsCompleted
-
Novartis PharmaceuticalsTerminated
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
University College, LondonNational Institute for Health Research, United KingdomActive, not recruitingLiver Transplantation | Renal FailureUnited Kingdom
-
Lexicon PharmaceuticalsCompletedDrug InteractionsUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)CompletedColorectal Cancer | Anal Cancer | Drug/Agent Toxicity by Tissue/Organ | Radiation EnteritisUnited States
-
Novartis PharmaceuticalsTerminated
-
Debiopharm International SAActive, not recruitingAcromegaly | GEP-NETUnited Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel